CRSP Today - Aug 06: Earnings Beat and Pipeline Buzz

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

CRSP Today - Aug 06: Earnings Beat and Pipeline Buzz

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly investor buddy. I’ve been in the game for a while, and today we’re chatting about CRISPR Therapeutics, ticker CRSP. So, how’d they do today? Well, it was a green day, but not by much—just a tiny bump up of about 0.27%.

Now, what’s the scoop? So, CRISPR dropped their Q2 earnings, and guess what? They beat estimates! That’s always a good sign, right? Their revenues were looking solid, and that kind of news usually gives investors a little boost of confidence. It’s like when you ace a test you thought you’d bomb—definitely a reason to smile.

But wait, there’s more! The buzz around their drug CASGEVY is heating up, especially after some pipeline updates. People are really excited about its expansion, and it seems to be gaining traction. That’s likely why the stock got a nice little bump earlier in the week—investors are feeling optimistic about its potential. Plus, Piper Sandler is still on board with a "buy" rating for CRSP. That’s like getting a thumbs up from your favorite teacher.

So, what's on the horizon? Well, there’s chatter about CRISPR’s sales growth for CASGEVY and their in vivo expansion with CTX310. Those are some big moves that could really shape the company’s future.

In a nutshell, CRISPR is looking solid right now, even if today’s gain was a bit on the chill side. As always, remember: this is just for fun and info—no financial advice here! Catch you later, folks!

まだレビューはありません